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LIST OF ABBREVIATIONS 
 
 
4-AP 4-aminopyridine 
ADC apparent diffusion coefficient 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazol propionate 
ANOVA analysis of variance  
AOI area of interest 
AQP4 aquaporin-4 
BBB blood-brain-barrier 
CA cornu Ammonis 
DMSO dimethyl-sulphoxide 
DWI diffusion-weighted imaging 
EEG electroencephalography 
EM electron microscopy 
GABA γ-amino-butyric acid 
GLU glutamate 
GTCS generalised tonic-clonic seizure 
i.p. intraperitoneal 
IEG immediate early gene 
IR immunoreactive 
fMRI functional magnetic resonance imaging 
NMDA N-methyl-D-aspartate 
PCR polymerase chain reaction 
PV parvalbumin 
RARE rapid acquisition-rapid enhancement 
rCBF regional cerebral blood flow 
rCBV regional cerebral blood volume 
ROI region of interest 
SE status epilepticus 
T2 transverse relaxation time 
T2W T2-weighted (imaging) 
TE echo time 
TR repetition time 
vs. versus 
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1. INTRODUCTION 
 
The excessive, pathologic oversynchronisation of neuronal activity and the disequilibrium 
between certain excitatory and inhibitory factors are considered as the pathophysiologic 
basis of the epileptiform activity in the central nervous system. The conventional therapeutic 
regimes concentrate on the strengthening of the inhibitory neurotransmission whereas the 
inhibition of the excitatory responses is under current research, but results are mainly 
available about the role of NMDA -mediated events. 
One of the well-known chemical means to elicit acute seizures with generalised tonic-clonic 
features in an in vivo animal model is the 4-aminopyridine (4-AP), having well-circumscribed 
pharmacokinetic and pharmacodynamic properties. 4-AP is a nitrogen-containing 
heterocyclic K+-channel blocker, exerting its effect mainly via IK(A) and IK(V) channel types, 
thus the shift of the membrane potential towards depolarisation enables Ca2+-influx; mainly 
via voltage-gated Ca2+-channels and the NMDA receptor ion channels, the latter are opened 
by the mainly presynaptically acting 4-AP-induced membrane-depolarisation. The sustained, 
repeated, synchronised neuronal discharge, the so-called “burst firing” is a basic feature of 
the central nervous system seizure mechanism. The prolonged neuronal depolarisation 
stimulates both excitatory and inhibitory neurotransmitter release, especially glutamate 
(GLU) and reinforces the inhibitory and excitatory postsynaptic potentials. 
According to our microdialysis investigations, fast and highly significant elevation can be 
demonstrated in the striatal concentration of GLU. Since many of the excitatory afferents of 
the striatum originate from the cerebral cortex (and thalamus), we may suppose that the 
elevation in the striatal GLU is consequence of neocortical hyperactivity and the excessive 
release of the transmitter from corticostriatal (and thalamostriatal) axon terminals. 
Interestingly, the GLU level reaches its maximum at 120 min, well after the cessation of the 
electrographic seizure. This explains the long-lasting spiking activity on the striatal EEG and 
raises the possibility that besides the postsynaptic depolarization, GLU might regulate the 
release of other transmitters through metabotropic GLU receptors.  
The immediate early gene (IEG) c-fos is an inducible transcription factor playing important 
role in certain nuclear regulative processes. The gene products of the IEGs, via 
transcriptional regulation influence the genes involved in the maturation and adaptation 
mechanisms of the nervous system, or in plasticity and neurodegeneration, as well as in 
epilepsy. The full spectrum of the genes regulated by c-fos is not known as a whole. 
Nevertheless, the signal transduction characteristics and the intracellular pathways of c-fos 
gene expression are basically understood. The c-fos mRNA transcription shows strict 
correlation with the electrophysiologically proven cellular activity, and this correspondence 
establishes the Fos protein (appearing in the cell nuclei of the neurons concerned) as a 
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sensitive marker of the increase of neuronal activity. NMDA and AMPA receptors are 
amongst the external signals, which activate c-fos transcription. 
Amongst the earliest neuropathological changes in seizure activity, the swelling of the 
astrocytic processes has already been observed. Astrocytes are the main cell types that 
swell in cytotoxic brain oedema, especially the pericapillary foot processes, which are the 
predominant sites of aquaporin-4 (AQP4) expression in the brain. Glutamate, at similar 
concentrations required to induce neuronal cell death, has been shown to increase cell 
volume in cultured astrocytes. The astrocytic swelling has numerous deleterious secondary 
effects, such as the release and decreased uptake of excitatory amino acids; worsening the 
micro-environmental circumstances like a circulus vitiosus process. Pharmacological 
inhibition of seizure activity decreases brain oedema in different animal models. Beside the 
electron microscopic investigations, the importance of the in vivo imaging techniques, such 
as functional magnetic resonance imaging is continuously increasing.  
Studies involving intracellular recording in rat neocortical slices have shown that NMDA 
receptors contribute to the process of stimulus-induced paroxysmal depolarisation shift 
(PDS) amplification by prolonging the duration and reducing the latency of the epileptiform 
discharge. The high-affinity open-channel NMDA receptor blocker dizocilpine maleate (MK-
801) is also potent anticonvulsant and protects against seizure-related brain damage. The 
MK-801 is widely used for NMDA receptor mapping in imaging studies; or to establish an 
experimental schizophrenia in animal models. 
The compound GYKI 52466 is a selective, non-competitive, presumably allosteric antagonist 
of the AMPA-subtype ionotropic glutamate receptors; with good blood-brain-barrier (BBB) 
permeability, neuroprotective effects in seizure and cerebral ischaemia, antinociceptive and 
anti-inflammatory properties and has other advantageous effects in ischaemic conditions. 
Electrophysiological investigations proved the antagonistic activity of GYKI 52466 upon the 
AMPA and kainite receptors, whereas practically no effect has been demonstrated on the 
NMDA receptors, metabotropic glutamate receptors, and on the GABAA-receptors.  
Synapses in cerebral cortex and hippocampus commonly coexpress NMDA and AMPA 
receptors. According to this observation, the proconvulsive feature of glutamate-receptor 
agonists; and the anticonvulsive effect of the glutamate-receptor antagonists have been 
proved in several in vivo  and in vitro models of experimental epilepsy.  
In our former studies the NMDA-subtype ionotropic glutamate receptor antagonists  in 
pretreatment significantly decreased the expression of c-fos in the examined neo- and 
allocortical areas in the 4-aminopyridine acute convulsive rat model; and in the same time, 
the latency of the GTCS was significantly increased (dextrometorphan, ketamine) or the 
GTCS occurrence was significantly reduced (MK-801), as well.  
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2. OBJECTIVES 
 
A. Based on the success of our cooperating partners in the fMRI description of the pilocarpin 
epilepsy paradigm, we proposed a pilot experiment for the fMRI study of the 4-AP acute 
convulsion model concerning the changes in the regional cerebral blood flow (rCBF) and 
apparent diffusion coefficient (ADC) regarding the water movements (extra- and intracellular 
oedema).  
 
B. The aim of the AMPA receptor antagonism study was to assess the antagonism of 
another well-characterised glutamate receptor, the AMPA receptor in a similar (4-AP-induced 
acute convulsion) paradigm. According to the time-course of the GYKI 52466 anticonvulsive 
efficacy, and based on our preliminary data we focused on the investigation of the short-term 
effects (c-fos expression and pericapillary astrocyte swelling) within the very first hour of 
seizure initiation. To evaluate the activation status changes of the inhibitory cells in the 4-AP 
paradigm, we also investigated the effect of the AMPA receptor antagonism by assessing the 
c-fos expression pattern of the immunohistochemically well-detectable parvalbumin (PV)-
positive cells representing a subpopulation of GABAergic interneurons. 
 
C. The NMDA antagonists significantly decreased seizure-related astrocyte swelling in the 
cerebral cortex, so we are going to compare the efficacy of NMDA and AMPA receptor 
antagonism on the astrocyte swelling and neuronal activation (c-fos expression) associated 
with acute convulsions. 
 
3. MATERIALS AND METHODS 
 
3.1 Functional and structural MRI measurements in the 4-AP paradigm  
 
The MRI experiments were performed in the Experimental MRI Laboratory of the Department 
of Anatomy and Histology, Faculty of Medicine, University of Verona, Verona, Italy. Male 
adult Wistar rats (80–90 days of age) were kept under controlled environmental parameters 
and veterinarian control. The experiments received authorization from the Italian Ministry of 
Health. Rats were randomly divided into two groups: in twelve rats, seizures were elicited 
with a single intraperitoneal (i.p.) bolus of 4-AP (5 mg/kg), dissolved in physiological saline 
(0.67 mg/ml). Control animals (n = 12) received the same volume of physiological saline i.p. 
MRI analysis was performed 2 h, 24 h and 3 days after seizure arrest. Twelve animals for 
both conditions were analysed with structural (T2W and DWI) and functional (rCBV) MRI. For 
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MRI data, difference between DWI, T2W and rCBV values obtained in control vs. 4-AP-
treated rats was evaluated with one-way analysis of variance (ANOVA) for repeated 
measures followed by the LSD post-hoc test, setting the significance at p < 0.05.  
 
3.2 Administration of the glutamate-receptor antagonists 
 
The animal experiments were conducted in accordance with prevailing laws and ethical 
considerations. The animals were maintained under standard animal housing conditions, with 
ad libitum access to food and water. The experiments were performed on male Wistar rats 
weighting 200-250 g. The convulsant agent 4-AP was administered i.p., in 5 mg/kg dose. The 
non-competitive NMDA receptor antagonist MK-801 was dissolved in physiological saline 
and administered i.p. in a volume of 1 ml, 10 min prior to the application of 4-AP in 1 mg/kg 
dose. The non-competitive AMPA receptor antagonist GYKI 52466 was dissolved in 50% 
DMSO (dimethyl-sulphoxide) dilution (3.33 or 6.67 mg in 1 ml vehicle), and administered i.p. 
15 min before 4-AP injection, in 25 or 50mg/kg dose, respectively. 
For the MK-801-pretreatments, the animals were randomly divided into three groups. In the 
first group, the animals (n=18) were pretreated with 1 mg/kg MK-801; and 10 min later, the 
convulsant 5 mg/kg 4-AP was administered. The control group (n=18) received the solvent of 
MK-801 and 5 mg/kg 4-AP. The experiments were finished 1, 3 and 24 h after the 4-AP 
injection (6-6-6 animals pro every time group). At the end of the experiments, three-three 
animals from every group were sampled for PCR or were processed for electron microscopy, 
respectively.  
For the GYKI 52466-pretreatments, the animals were randomly divided into three groups. In 
the first two groups, the animals (10 per group) were pretreated with 25 mg/kg or 50 mg/kg 
GYKI 52466, respectively. 15 min later, the convulsant 5 mg/kg 4-AP was administered. The 
control group (10 animals) received the solvent of GYKI 52466 and 5 mg/kg 4-AP. The 
experiments were finished 1 h after the 4-AP injection, within the range of the presumed 
maximal anticonvulsive effect of the GYKI 52466.  
For the immunohistochemical evaluation of the possible individual c-fos expression effect of 
the applied antagonists, another four control groups have been established (N=4 in each 
group), as follows: animals receiving physiological saline only (1 ml for an animal with 200 g 
bodyweight), animals receiving 50 mg/kg GYKI 52466 only, animals receiving 1 mg/kg MK- 
801 only and animals receiving 5 mg/kg 4-AP only. These animals have been sacrificed 1 h 
after the injection and processed for immunohistochemistry or electron microscopy as 
described below. 
The behavioural outcome of the pretreatment with the AMPA antagonist was observed up to 
1h after the 4-AP injection. The onset of the GTCS was always sudden and clear-cut, so the 
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latency of GTCS was easily measurable. The GTCS latency was statistically evaluated with 
one-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test (significance 
criterion was 0.05). The GTCS occurrence and overall mortality data were analysed with the 
Fisher’s exact probability test (significance criterion was 0.05).  
On the coronal brain slices c-fos and parvalbumin double-labelling immunohistochemistry 
was carried out. Quantitative analysis was performed on five sections per animal (N=4; the 
mean data per each animal was used in the statistical analysis). Areas of interests (AOIs) for 
counts of immunostained neuronal nuclei were selected form the S1Tr region of the parietal 
neocortex, regions CA1, CA2 and CA3 of the Ammon’s horn and from the hilus and granule 
cell layer of the dentate gyrus. Differences in the number of c-fos positive or c-fos and 
parvalbumin double-positive cells in the control and in the antagonist-pretreated were 
analysed with one-way analysis of variance (ANOVA), followed by the Bonferroni post hoc 
test. A significance criterion of 0.05 was used.  
Samples of the right parietal neocortex (for MK-801 experiments); or right parietal neocortex 
and hippocampus (for GYKI 52466 experiments) were prepared for electron microscopy. 
These samples were analysed by a Philips TM10 transmission electron microscope 
(Eindhoven, Netherlands). Photographs were taken with a computer assisted digital camera 
(MegaView II, Soft Imaging Systems, Münster, Germany). Approximately 900 µm2 of sample 
surface was viewed systematically through all neocortical layers of the parietal cortex or in 
the hippocampus; 4 EM preparates per animal (N=4) was examined and the mean data of 
the altogether 14 ± 2 capillary cross sections per each animal was used in the statistical 
analysis. One-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test, 
(significance criterion: p<0.05; SPSS 9.0 statistical software) was performed on the 
measured area data (area of capillaries, area of the swollen pericapillary astrocytic endfeet). 
 
4. RESULTS 
 
4.1 Structural MRI of the 4-AP model 
 
4.1.1 T2 maps 
 
Quantitative T2 maps calculated from multi-echo spin-echo acquisitions clearly showed the 
overall pattern of changes in control and epileptic rats (both at 2 h and 24 h), highlighting the 
signal increase throughout the cerebral cortex. The T2 value was also slightly increased in 
the amygdala. In the diencephalon, selective increase in the T2 signal was documented in 
medial thalamic regions. T2 values exhibited a 56% increase (p<0.001) in the parietal cortex 
at 2 h vs. control; this increase was still present (p<0.01) at 24 h (+29%). A dramatic increase 
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in the T2 values was found also in the hippocampus after 2 h (+72%, p<0.001) and after 24 h 
(25%; p<0.01). The temporal cortex showed the same pattern of alteration (+97%; p<0.0001 
at 2 h; + 39%, p<0.001 at 24 h). A highly significant (p<0.001) increase in T2 (52% at 2 h and 
33% at 24 h) was also found in the medial thalamus. In all of these structures, the T2 values 
observed 24 h after seizures were significantly higher than those observed in the controls 
(p<0.001). No evident differences were detected 3 days after seizure induction. 
 
4.1.2 Diffusion-weighted imaging 
 
Diffusion-weighted images, based on the sensitization of the MRI signal to the Brownian 
motion of water molecules, reveal maps of brain tissue water motion, resulting in 
hyperintense alterations. ADC maps of brain tissue water, calculated from DWI, showed 
consistent changes in ADC in the cerebral cortex (parietal cortex), hippocampus and 
amygdala of the epileptic animals at 2 h and 24 h  compared with control ones. An evident 
reduction of the average ADC value was documented in the parietal (-44%) and temporal (-
34%) cortices, hippocampus (-23%) and medial thalamus (-11%) 2 h after 4-AP-induced 
seizures. A further drop of ADC value was documented 24 h after 4-AP injections in the 
hippocampus (-46%), medial thalamus (-21%) and in the cerebral cortex (parietal: -57%; 
temporal: -64%). ADC values returned to basal levels 3 days after seizure onset. 
 
4.2 Functional MRI of the 4-AP model: rCBV maps 
 
Quantitative parametric maps reconstructed by images acquired with gradient-echo 
sequence before and after USPIO administration in control and epileptic animals at 2 h and 
24 h showed an increase of average blood volume value in the early stages of the seizures, 
with a progressive normalization of the values at 24 h in the parietal cortex and 
hippocampus. In the medial thalamus, the value failed to return to baseline 24 h post-
convulsions (p<0.001). 2 h after seizure onset, the values were higher in the parietal cortex 
(+32%, p<0.0001) and in the hippocampus (+16%, p<0.01) versus control. At subcortical 
levels, rCBV increased in the medial thalamus (+44%, p<0.0001). 24 h after seizures, rCBV 
showed marginal alteration in the parietal cortex (+4%) and hippocampus (+4%) but was still 
highly significantly (p<0.0001) increased (+21%) in the medial thalamus. No significant 
alterations were found 3 days after seizure onset. 
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4.3 Behavioural analysis of the pretreatments with GYKI 52466 
 
The i.p. administration of 4-AP causes characteristic behavioural symptoms within 15-20 min: 
increased exploratory activity, tremor of the vibrissal and masticatory muscles, followed by 
generalised tremor of the body musculature, observable as continuous fasciculation of the 
muscles, the more and more frequent clonuses and tonus changes of the limbs. The 
increasing motor symptoms lead to a “wild running” phenomenon and, finally, to generalised 
tonic-clonic seizures (GTCS), often preceded by vocalisation. With the dissipation of the tonic 
component, the clonic one becomes more dominant for a while with tenebrosity for other 10-
15 min until regaining normal activity. The gradual dissipation of the seizure activity can be 
detected electrophysiologically after 50-60 min; 90-100 min after the 4-AP injection, the 
animals recover. Nevertheless, approximately 20% percent of the control group animals die 
during or after GTCS, due to the seizure.  
The increase in the GTCS latencies of the GYKI 52466-pretreated groups is observable but 
statistically do not differ between the two dose groups, however, they represent a significant 
change compared with the control group. In the pretreated groups, the GTCS occurred in 
20% (25 mg/kg) or in 10% (50 mg/kg) of the animals, whilst in 80% of the 4-AP control 
animals (without GYKI 52466 pretreatment). According to the Fisher’s exact probability test, 
reduction in the number of animals (in which a GTCS occurred) in both groups administered 
GYKI was statistically significantly different from the number in the vehicle treated group.  
Nevertheless, there is no significant difference between the groups with different GYKI 52466 
doses. During the 1-hour observation, no recurrent GTCS was observed, the survival ratio 
was 100% in both pretreated groups, whilst 80% in the control group; which is, however, 
statistically not significant.  
Besides the local –presumably peritoneal– irritation (at the site of injection) dissipating within 
1-2 min after the DMSO administration (as vehicle in the control group), no long-lasting side-
effect of DMSO was noted, the animals displayed normal activity. As observable side-effects 
of the GYKI 52466 pretreatment, transient (approximately 15-20 min before regaining normal 
activity) ataxia, loss of coordination and reduction of the locomotor activity, together with 
apparently sedative effect (decreased vigilance) were noted.  
 
4.4 Immunohistochemistry of the pretreatments with GYKI 52466 
 
The lower dose GYKI 52466 pretreatment (25 mg/kg) significantly increased, whereas the 
higher dose pretreatment (50 mg/kg) significantly decreased the number of c-fos-IR cell 
nuclei in the neocortex. In laminar distribution, the laminae II-III and V-VI showed this 
significant decrease with the higher dose (the decrease in the lamina IV was not significant). 
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The lower dose pretreatment yielded significant increase in the lamina V only, the other 
changes are statistically not significant. In the lamina I, no change was detectable in both 
cases. As for the c-fos and PV double-positive cells, the lower dose pretreatment had no 
effect while the higher dose pretreatment caused a significant decrease in the double-
immunoreactive cell counts. This change was significant only in the lamina II for the lower 
dose, whereas in the laminae II-VI for the higher dose pretreatment. 
In the hippocampal sectors CA1-3 and in the hilus of the dentate gyrus even the lower dose 
GYKI 52466 pretreatment caused significant reduction not only in the number of the c-fos-IR 
cell nuclei; but also in the number of the double-labelled cells. This c-fos-IR count change is 
even more pronounced in the granular layer of the dentate gyrus: control c-fos-IR nuclei 
(3535 per mm2; 100%) vs. GYKI 52466-pretreatment with 25 mg/kg (1401 per mm2; 39.6% of 
the control) or with 50 mg/kg (184 per mm2; 5.2% of the control).  
The control groups (receiving physiological saline only or 50 mg/kg GYKI 52466 only or 1 
mg/kg MK-801 only; without seizure induction with 4-AP) show no significant difference 
compared to one another, so the effect of antagonists given alone does not differ statistically 
from that of the physiological saline in this acute convulsion paradigm. 
  
4.5 Electron microscopy of the pretreatments with MK-801 or GYKI 52466 
 
The swelling of pericapillary astrocytic endfeet (i.e. the increase of the area occupied by 
astrocytic glia limitans) was significantly reduced in the groups with MK-801-pretreatment 
compared to the 4-AP controls at any observed time point. Regarding the capillary areas, 
there was no significant difference between the animal groups with and without MK- 801-
pretreatment at 1h and after 24h. The only significant change at 3h indicates that the MK-
801-pretreatment significantly reduced the capillary lumen compression due to pericapillary 
oedema. This difference is also significant between the 1h and 3h pretreated groups.  
In the case of the neocortical capillary areas, there was no significant difference amongst the 
4-AP control and the GYKI 52466-pretreated groups. The swelling of pericapillary astrocytic 
endfeet in the neocortex was significantly increased in the group with lower dose of GYKI 
52466-pretreatment compared to the vehicle + 4-AP controls, whereas there was no 
significant difference between the control and the 50 mg/kg GYKI 52466-pretreated groups. 
Measuring the hippocampal capillary areas, there was a significant difference between the 
25 mg/kg GYKI 52466-pretreated and the 4-AP control group (significant decrease in the 
group that received the AMPA antagonist), whereas there was no such difference between 
the higher dose pretreatment and the 4-AP control group. In the hippocampus, no significant 
alteration can be detected between the three groups.  
 
10 
Summary of Ph.D. Thesis 
5. DISCUSSION 
 
5.1 Functional and structural MRI in the 4-AP acute convulsion paradigm 
 
Structural alterations were studied by T2W RARE images that were already reported to be 
sensitive in detecting epileptic alterations. T2W maps indicate that the peak of T2 alterations 
occurs 2 h after seizures, whereas 24 h after seizures, these values are decreased close to 
baseline levels. In the chronic epilepsy models, the alterations of the T2W maps are more 
evident at 24 h after seizures, compared to our present findings in the 4-AP model. This fast 
recovery in T2W images would be consistent with the absence of an epileptogenic phase 
and reflected a reduced severity of the oedema following brief, acute seizures. The ADC 
alterations reflect pathological conditions in brain tissue that are only partially understood and 
involve changes in the diffusion characteristics of intra- and extracellular water 
compartments, water exchange across permeable boundaries and changes in volume 
transmission. In general, reduction of the ADC has been associated with acute cytotoxic 
oedema. The present findings of decreased ADC values in the cerebral cortex can be 
explained with cytotoxic oedema. The swelling of the astrocytes, and the oedema of the 
perivascular glia limitans, suggest the presence of excess amounts of excitatory transmitters, 
metabolites (CO2) and K+ in the extracellular space. On the basis of the morphological 
results, we conclude that the brief, acute seizures caused cellular oedema of the astrocytes 
mainly. The swelling of the astrocyte obliterated brain extracellular spaces; inhibiting the 
clearance of transmitters, ions and HCO3- from the extracellular space, contributing to and 
enhancing the cellular damage. However, the astrocyte that has taken up glutamate from the 
extracellular space may release it again through connexon-hemichannels. Therefore, the 
astrocyte may sustain a long-lasting decrease in volume transmission. These changes may 
explain the long-lasting decrease of the ADC values in our experiments. The decrease of the 
capillary diameter impairs the local microcirculation and could contribute to the decrease of 
ADC values. The partial mismatch between the altered DWI values and the minor astrocytic 
swelling detected by histological analysis at 24 h may be partially explained by a dehydration 
process that affects the oedema evaluation, allowing only the detection of the more obvious 
alterations. The increase of rCBV at the same time may reflect the compensatory effects of 
the local changes at the level of the arterioles and larger vessels. In order to better 
understand CBV data, it should be considered that oedema results in the decrease of the 
diameter of microvessels in the affected regions, thus inducing a relative ischaemia, and a 
compensatory hyperperfusion in adjacent areas may be hypothesized. Taken together, our 
data show that brain damage following SE involves several presumably pathological 
processes operant in both limbic and extra-limbic regions, suggesting that sustained seizure 
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activity elicits a complex rearrangement of cortical and subcortical neural networks. The 
ultrastructural changes indicate different processes controlling diffusion properties of the 
extracellular spaces.  
 
5.2 Effect of the pretreatment with glutamate-receptor antagonists on the seizure-associated 
symptoms and seizure outcome 
  
According to our former results, the non-competitive NMDA receptor antagonists MK-801      
(given in pretreatment) significantly reduced the number of animals displaying GTCS without 
prolonging the seizure-latency. After the intraperitoneal administration of MK-801 the first 
characteristic symptoms: muscle hypotonia and unsteady gait, slight impairment of postural 
control with stereotypic, repeated movements of the head; due to the psychotomimetic 
(phencyclidine-like) side effects of MK- 801 developed, followed by mild tremor. The animals 
treated with MK-801 rarely developed generalized tonic-clonic convulsions; muscle tremor 
being the main symptom throughout the experiment. 
The GYKI 52466 increased the latency of the first GTCS (however, without dose-dependent 
difference); no GTCS recurrence was observed (if there was GTCS event; only one GTCS 
per animal was registered during the observation).  The seizure survival of the pretreated 
animals was 100%, however, in this case there is no significant change compared to the 
survival of the control group animals (80%). As for side-effects of the AMPA antagonist 
pretreatment, decrease in the locomotor activity and muscle tone were observed, likely due 
to the formerly described central muscle relaxant effect. Probably, this property can be 
responsible for the visible reduction of the tonic seizure component, and the dominance of 
the clonic component in the GTCS of the pretreated animals. Moreover, GYKI 52466 was 
found to be effective in different models of epilepsy only in doses impairing motor function. 
Nevertheless, the possibility that DMSO eventually potentiates not only the efficacy, but also 
the side-effects of GYKI 52466 cannot be entirely excluded. According to literature data, 
higher doses are needed for the moderation of the clonic components, than for the tonic 
components.  
 
5.3 Effect of the pretreatment with glutamate-receptor antagonists on the seizure-associated 
neuronal activation 
 
MK-801 caused an overall decrease of Fos immunoreactivity (layers II-III, IV, VI, less 
markedly in layer V). Pretreatment with MK-801 resulted in a significantly lower number of 
Fos-labelled neurons in CA1, CA2 and CA3 regions of the Ammon’s horn with respect to the 
animals that had received 4-AP only. Pretreatment with MK-801 reduced Fos 
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immunoreactivity in the dentate granule cell layer, as confirmed by statistical evaluation. 
Moreover, MK-801 resulted in a significant decrease of the number of Fos-containing cell 
nuclei in the dentate hilus. When given alone, the MK-801 caused only minimal cortical and 
hippocampal Fos induction. The number of stained cells induced by MK-801 was consistently 
very low, without significant differences. 
As for GYKI 52466, to explain the dose-dependent c-fos-IR differences in the neocortex; we 
presume (1) different activity states of the AMPA receptors, depending on the number of 
modulatory molecules bound by the receptor subunits. In addition to, we also think that (2) 
the lower dose of GYKI 52466 is ineffective in the presence of the high glutamate 
concentration associated with the early seizure activity. The GYKI 52466 seemed to be more 
effective in delaying the first ictal event, whereas, the propagation of the seizure activity or 
IEG induction seemed to be facilitated in the lower dose pretreatment group. According to 
the literature, the AMPA receptors are rather involved in the initiation than in the 
maintenance of seizure (mirrored in our behavioural data for increasing seizure latency and 
reducing GTCS occurrence); whereas the NMDA receptors play crucial role especially in the 
maintenance and propagation of seizure (reflected in the cellular gene expression changes 
and EM morphology alterations). The majority of the AMPA receptors can be found in the 
cells of laminae II-III and V-VI. The efficacy of the higher dose AMPA antagonism also refers 
to the importance of AMPAergic excitation in these neocortical strata. The intracortical 
networks are mainly mediated by NMDA receptors; these connections remain active in spite 
of the presence of GYKI 52466. The induction of 4-AP-induced synchronous network activity 
in the lower neocortical layers is rather dominated by the excitatory, whilst in the superficial 
ones, by the inhibitory components. At the lower dose of GYKI 52466, therefore, we suppose 
(3) a local disequilibrium between the efficacy of AMPA receptor antagonism within the 
inhibitory population and the overall (rather dominated by the excitatory cells) population, 
resulting in the overall activation status change reflected by the c-fos-IR differences. The 
predominance of non-NMDA receptor-mediated excitatory inputs arising from bursting 
neurons was shown on the fast-spiking GABAergic interneurons; these cells are also strongly 
excited by thalamic afferents. The inhibitory neurons responsible for surrounding inhibition 
were less activated under the influence of GYKI 52466. Nevertheless, we found that these 
interneurons possessed similar AMPA receptor properties to those of the pyramidal cells: the 
50 mg/kg dose was needed to significantly decrease the cellular activation. This local 
balance-shift may also be complicated by the slightly different laminar responses to 4-AP, 
since the neocortical PV-containing GABAergic interneurons constitute a heterogeneous 
population concerning the expression pattern of voltage-gated K+-channel subunits  in the 
different neocortical laminae.  
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In the hippocampal areas studied, even the lower dose of GYKI 52466 was efficient to 
reduce the c-fos immunoreactivity, not only in the parvalbumin-labelled, but also in the whole 
c-fos-IR neuronal population, especially in the granular layer of the dentate gyrus. This fact 
emphasises the differences in the receptorial distribution and spatial separation of excitatory 
and inhibitory axon systems in the hippocampus. According to immunostaining data, AMPA 
receptors are concentrated in the outer molecular layer of the dentate gyrus and in the 
stratum lacunosum-moleculare of the regio superior, while NMDA receptors are relatively 
scarce in the same regions. These layers are the main excitatory input areas: the axon 
terminals of the perforant path synapse here. The prominent contribution of the AMPA 
receptors to the activation of the neuronal circuits is shown by the significant reduction of the 
number of the c-fos-IR cells of the hippocampal CA1, CA2 and CA3 sectors and in the 
stratum granulosum and hilus of the dentate gyrus, even by the lower (25 mg/kg) 
pretreatment dose.  
 
5.4 Effect of the pretreatment with glutamate-receptor antagonists on the seizure-associated 
pericapillary astrocytic swelling 
 
Our investigations revealed the importance of brain swelling in 4-AP seizures: the long-
lasting astrocyte swelling was responsible for the critical decrease of ADC values, as shown 
by our MRI experiments. Regional differences in astrocytic swelling are likely due to the 
various astrocytic capacities for glutamate metabolism, neurotransmission and aquaporin-
synthesis. The mechanism of seizure-related astrocyte swelling is likely to be multifactorial; 
such as (1) circulatory and (2) metabolic changes due to seizure activity. Alternatively, the 
astroglial volume-change may be secondary to (3) the failure of these cells to manage the 
consequences of increased neuronal activity, thus providing a mechanism reinforcing seizure 
per se. Literature data are limited concerning the roles of AMPA receptor antagonism in the 
seizure-related pericapillary astrocyte swelling; whilst the action of the NMDA receptor 
antagonists influencing the glia-to-neuron signalisation processes or the changes of the brain 
water compartments, or modulating the pericapillary astrocytic swelling following injuries or 
following glutamate-administration have already been described. The glutamate-induced 
astrocytic swelling can be moderated with MK-801. In accordance with these data, we 
demonstrated the long-term astrocytic oedema-reducing effect of the MK-801-pretreatment in 
the 4-AP-induced seizure. The capillary area enlargement was limited to the 3h pretreatment 
group; this alteration may reflect a short-term perfusion change at the affected sites.  
In our GYKI 52466 experiments, the AMPA blockade was completely ineffective to decrease 
the seizure-related astrocyte swelling – in the neocortex GYKI 52466 even increased the 
swelling of the astroglia. Other studies also question the protective effect of GYKI 52466 
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against seizure-related morphological damage, which is a contrasting feature with the 
anticonvulsant efficacy of this compound.  On the other hand, the above described results 
from our laboratory proved that in the same experimental conditions NMDA blockade with 
MK-801 decreased brain oedema significantly, indicating the differences between roles of the 
ionotropic receptors, and the significance of glutamate. Thus, the overactivation of NMDA 
receptors is suggested mainly in the background of the morphological changes of the 4-AP 
paradigm. 
 
6. CONCLUSIONS 
 
In our pilot study we have described the properties of the 4-AP-evoked seizure activity in the 
rat brain by means of structural and functional MRI. These are the first MRI data about the 
4-AP acute convulsive model, providing information for further experiments about the 
possible treatment options in this rat convulsion paradigm. 
On the basis of these results, we conclude that astrocyte swelling is unlikely to be mediated 
by AMPA receptors, and blockade of the AMPA receptor does not protect against 
astroglial swelling in epilepsy. Further investigation should elucidate the role of astrocytic 
glutamate receptors in the 4-AP-elicited acute convulsions and the pathophysiology of 
astrocytic oedema associated with generalised tonic-clonic seizures.  
Summarizing our results, it seems that the main protective effect of GYKI 52466 is based 
on the moderate inhibition of seizure activity only (increasing the latency of the GTCS, 
and decreasing the lethality in the animal groups); although the relatively short duration of 
action may also have contributed to the limited effects of GYKI 52466. This notion, 
concerning the low therapeutic index of GYKI 52466, is supported by the literature. Our data 
suggest that the seizure-associated cellular damages (such as astrocytic swelling) 
depend critically rather on the participation of NMDA receptors, than on the AMPA 
receptors. In the hippocampus, cellular activation was rather dependent on AMPA 
receptors than in the neocortex, but astrocyte swelling was not. We think therefore, in 
accordance with the literature that the AMPA receptors are rather involved in the initiation, 
than in the maintenance and propagation of cortical seizure activity. The different extent of 
participation of AMPA receptors in organising neuronal circuits of neocortex and 
hippocampus in convulsions is reflected by the dissimilar GYKI 52466 efficacy in reducing 
the seizure-related neuronal activation. By our experience in the 4-AP convulsion paradigm, 
rather the antagonists of the NMDA than AMPA receptors play crucial role in circumventing 
the acute morphological changes, such as astrocytic swelling.  
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